Investors | UCB
This section is intended for media and financial analysts
UCB on a Growth Path for a Decade+
Creating value in the lives of the people we serve, now and into the future
UCB is driven to ensure that everyone can live the best life they can, as free as possible from the challenges and uncertainty of a disease. This ambition fuels our purpose: creating value in the lives of the people we serve, now and into the future.
Our research and development activity across neurology, immunology, and other areas where our expertise aligns with unmet needs is driven by our connection to the people we serve. Their unique and diverse perspectives serve as guides and inspiration as we explore the furthest reaches of science and medical knowledge
UCB share price
UCB share price
| Price | Change |
|---|---|
| 210.60 € | -4.58% |
| Previous Close: | 220.70 |
| Open: | 222.00 |
| High: | 222.00 |
UCB’s Decade+ of Growth: Elevating lives of people through our medicines
Disclaimer
This website contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.
Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.
UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
Our key medicines
We bring solutions to people living with neurological or immunological diseases.
Growth drivers
BIMZELX® (bimekizumab)
Reaching more than >135 000 patients globally in H1 2026Indications: Psoriasis (PSO); Psoriatic Arthritis (PsA); Ankylosing spondylitis (AS); non-radiographic Axial Spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS)
Loss of Exclusivity (indicative): 2035 in U.S., without patent term extension; 2036 in Europe, 2037 in Japan
Sales: € 1.52 billion in HY 2026
Peak sales guidance: > € 7 billion
EVENITY® (romosozumab)
Reached more than 1 500 000 patients globally since launchIndication: Osteoporosis
Loss of Exclusivity (indicative): 2031 in Europe and Japan, 2033 in U.S.
Sales: € 88 million in HY 2026 in Europe. Net sales outside Europe reported by Amgen and Astellas
FINTEPLA® (fenfluramine)
Reaching more than 16 000 patients globallyIndications: Dravet Syndrome, Lennox-Gastaut Syndrome.
Loss of Exclusivity (indicative). 2032 in Europe and Japan, 2033 in U.S.
Sales: € 239 million in HY 2026.
Peak sales guidance: € 800 million by 2027.
RYSTIGGO® (rozanolixizumab)
Launched in the U.S. in July 2023, approved and launched in Europe and JapanIndication: generalized Myasthenia Gravis.
Loss of Exclusivity (indicative): 2037 in Japan. 2034 in Europe and 2035 in U.S., all without patent term extension.
Sales: € 192 million in HY 2026.
ZILBRYSQ® (zilucoplan)
Global launches started April 2024Indication: generalized Myasthenia Gravis.
Loss of Exclusivity (indicative): 2035 in Europe, U.S. without patent term extension. Japan 2040.
Sales: € 139 million in HY 2026
Solid foundation
BRIVIACT® (brivaracetam)
Indication: Epilepsy partial-onset seizure, also known as focal seizureLoss of Exclusivity (indicative): August 2026 in Europe & U.S. and 2034 in Japan
Sales: €327 million in HY 2026
Peak sales guidance: ≥ € 600 million by 2026, reached 2 years ahead of time
CIMZIA® (certolizumab pegol)
Indications: Ankylosing spondylitis (AS); non-radiographic Axial Spondyloarthritis (nr-axSpA); Crohn's disease (CD); Psoriasis (PSO); Psoriatic arthritis (PsA); Rheumatoid arthritis (RA)Loss of Exclusivity (indicative): 2026 in Japan.
Sales: € 954 million in HY 2026
KEPPRA® (levetiracetam)
Indications: Epilepsy partial-onset seizures, also known as focal seizures; Epilepsy primary generalized tonic-clonic seizures; Epilepsy myoclonic seizuresSales: € 216 million in HY 2026
NAYZILAM® (midazolam nasal spray)
Indication: Epilepsy seizure clustersLoss of Exclusivity (indicative): 2028 in U.S.
Sales: € 81 million in HY 2026
VIMPAT® (lacosamide)
Indications: Epilepsy partial-onset seizures, also known as focal seizures; Epilepsy primary generalized tonic-clonic seizuresLoss of Exclusivity: 2022 in Europe & U.S. 2024 in Japan
Sales: € 105 million in HY 2026
Our clinical development partnerships
- Press Release: Partnership with Amgen
- Press Release: Partnership with Biogen
- Press Release: Partnership with Cancer Research UK
Our clinical development pipeline
UCB remains committed to advancing innovation and delivering meaningful solutions for people living with severe immunological and neurological diseases. This commitment is reflected in its robust clinical development pipeline, further strengthened by the recent acquisitions of Candid Therapeutics and Neurona Therapeutics, which add next-generation therapeutic modalities to the portfolio. An overview of key clinical development milestones, including regulatory submissions, expected data readouts and pipeline advancements since January 1, 2026, is provided below. Updates and changes to UCB’s clinical development pipeline are outlined below.
General information
All medicines must pass safety and efficacy tests if they are to be approved by regulators. This is done through a series of rigorous clinical studies, also referred to as clinical trials, research studies or medical research.
Clinical studies index
UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.
bimekizumab (IL-17 A/F)
Monoclonal antibody
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.
Immunology
Hidradenitis Suppurativa (>9y / 12y-18y)
Topline results in H1 2027
Monoclonal antibody
Monoclonal antibody
Immunology
Palmoplantar Pustulosis (PPP)
Topline results in 2028
Monoclonal antibody
Monoclonal antibody
Immunology
Psoriasis (6y-18y)
Topline results in H2 2027
Monoclonal antibody
Monoclonal antibody
Immunology
Juvenile Idiopathic Arthritis (2y-18y)
Topline results in 2028
Monoclonal antibody
rozanolixizumab (FcRn inhibitor)
Monoclonal antibody
Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.
Neurology
Myelin oligodendrocyte glycoprotein (MOG) antibody disease
Topline results in H2 2027 (event driven)
Monoclonal antibody
Monoclonal antibody
Neurology
Ocular myasthenia gravis
Phase 3 initiated - Topline results in 2029
Monoclonal antibody
fenfluramine (5-HT and sigma-1 receptors)
Small molecule
Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor
Neurology
CDKL5 deficiency disorder
Filed
Small molecule
Small molecule
Neurology
RETT-Syndrome
Phase 3 initiated - Topline results in 2029
Small molecule
dapirolizumab pegol (anti-CD40L antibody)
Monoclonal antibody
Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease.
Dapirolizumab pegol is being co-developed with Biogen.
Immunology
Systemic lupus erythematosus
Topline results of 2nd phase 3 in 2028
Monoclonal antibody
Dapirolizumab pegol is being co-developed with Biogen.
STACCATO® alprazolam (benzodiazepine)
Small molecule
STACCATO® alprazolam is an investigational drug-device combination using STACCATO® delivery technology with alprazolam, a benzodiazepine, that has the potential to be the first rescue treatment to be administered by a patient or caregiver in an out-patient setting to rapidly terminate (within 90 seconds) an ongoing seizure.
Neurology
Stereotypical prolonged seizures
Topline results in Q4 2026 / H1 2027 (event driven)
Small molecule
rezanecel (GABA interneuron cell therapy)
Cell therapy
Rezanecel is an investigational allogenic regenerative GABA interneuron cell therapy, administered in a one-time, minimally invasive delivery procedure designed to integrate into dysregulated neural circuits and restore inhibitory tone
Neurology
Mesial Temporal Lobe Epilepsy
Phase 3 to start in H1 2027
Cell therapy
bepranemab (anti-tau antibody)
Monoclonal antibody
Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein.
Neurology
Alzheimer's disease
Signal-confirming Phase 2 to start in H1 2027
Monoclonal antibody
Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein.
glovadalen (D1 receptor positive allosteric modulators)
Small molecule
Glovadalen is an investigational selective dopamine D1 receptor positive allosteric modulator. This orally available, brain-penetrant, small molecule is designed to enhance the potency of dopamine ‘when and where needed’ to activate the dopamine D1 receptor and thereby improve symptom control. It is being studied for the treatment of Parkinson's disease.
Neurology
Parkinson's disease
Positive Phase 2a. Next steps under evaluation
Small molecule
multi-specific antibody
Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.
Immunology
Atopic dermatitis
Phase 2b - Topline results (52-week) in 2028
multi-specific antibody
multi-specific antibody
Immunology
Non Cystic Fibrosis Bronchiectasis (NCFB)
Phase 2 initiated in Q3 2026 - Topline results in 2029
multi-specific antibody
multi-specific antibody
Immunology
Chronic Obstructive Pulmonary Disease (COPD)
Phase 2 initiated in Q3 2026 - Topline results in 2029
multi-specific antibody
cizutamig (BCMA x CD3 T-cell engager)
multi-specific antibody
Cizutamig is an investigational bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing plasma cells and B-cells
Immunology
Myasthenia gravis & Systemic autoimmune rheumatic disease associated interstitial lung disease
Phase 2 planned to start end 2026
multi-specific antibody
Cizutamig is an investigational bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing plasma cells and B-cells.